Paysign Earnings Reports

Paysign's Q4 2024 performance featured double-digit revenue growth driven by significant expansion in the patient affordability segment, while plasma revenue softened due to market normalization. The company posted $1.37 million in net income and ended the quarter with $10.77 million in cash.

Paysign reported a strong third quarter with a 23.0% increase in revenue and a 20.6% increase in adjusted EBITDA. The growth was driven by a 219.1% year-over-year increase in revenue from patient affordability programs and an improvement in gross margins.

Paysign reported a strong second quarter with a 29.8% increase in revenue and a 95.8% increase in adjusted EBITDA. Growth was driven by the plasma donor compensation business and the patient affordability business. The company is raising its full-year guidance due to this outperformance.

Paysign reported a 30% increase in revenue and a 135% increase in adjusted EBITDA compared to the first quarter of the previous year. The patient affordability business grew significantly, with a 305% rise in revenue, becoming a major growth driver for the company. The company confirmed its full-year revenue guidance to be in the range of $54.5 million to $56.7 million and adjusted EBITDA to be in the range of $8.0 million to $9.0 million.

Paysign reported a strong year with a 24% increase in revenue and a 21% increase in adjusted EBITDA. The patient affordability business experienced significant growth, and the company anticipates continued upward trajectory across all business units in the coming year.

Paysign reported a strong third quarter with a 17% increase in revenue year-over-year and a 29% improvement in net income. The company's growth was evident across all business segments, driven by higher donor rates in the plasma business and substantial revenue growth in the patient affordability segment.

Paysign reported a 28% year-over-year increase in revenue, driven by growth in its plasma and patient affordability businesses. The company is on track to meet its revenue and Adjusted EBITDA guidance for the year.

Paysign reported a 23% increase in revenue compared to the previous year, driven by expansion in the plasma and patient affordability verticals. The company's investments in the patient affordability business are expected to yield positive returns. The first quarter has historically been the weakest due to slower plasma donations during tax season.

Paysign reported strong financial results for Q4 2022, driven by continued growth in the plasma business and the expansion of patient affordability programs. The company added 91 new plasma centers during the year and more than doubled the number of active patient affordability programs.

Paysign reported impressive revenue growth and a return to profitability in Q3 2022, with gross margins increasing to 54%. The company benefited from organic growth in plasma centers, a full quarter of revenue from newly onboarded plasma donation centers, and increased activity at border locations due to a preliminary injunction.

Paysign reported strong Q2 2022 results with improvements in top and bottom lines and gross margins. The company onboarded a record number of new plasma donation centers and expects revenue to grow 27.5% over 2021.

Paysign reported positive Q1 2022 results with good revenue growth driven by the rebound of the plasma business and winning new deals and onboarding new plasma centers and pharma clients.

Paysign reported positive Q4 results with improving revenues, income from operations, EBITDA, and adjusted EBITDA. The balance sheet also improved sequentially. The company is optimistic about growth prospects in plasma, pharma, and other prepaid businesses.

Paysign reported a solid Q3 2021 with improvements in revenue, loss from operations, EBITDA, and adjusted EBITDA both sequentially and year-over-year. Total revenue for the quarter was $7.8 million, a 16.8% increase from the previous quarter. The company is raising its gross profit margin forecast by 250 basis points to 49.0%.

Paysign reported improved revenues and operating results for Q2 2021, benefiting from the phasing out of pandemic-related stimulus. The company is focused on diversifying its business and investing in long-term growth, with the renewal of a major pharmaceutical hub customer and the addition of five new pharmaceutical copay programs expected to launch between now and the end of 2021.

Paysign reported financial results for the first quarter of 2021, which were negatively impacted by stimulus measures. However, the company is optimistic about a rebound as vaccinations increase and restrictions lift. Paysign added three new plasma centers during the quarter and expects to add a total of 60 new plasma centers this year. The company anticipates revenue to reach between $29.0 million and $32.0 million for the full year 2021.

Paysign's Q4 2020 results were impacted by the COVID-19 pandemic, particularly affecting clients in the pharma and plasma industries. The company added 55 new plasma programs and experienced a net growth in card programs of 61. Paysign remains well-capitalized with $7.8 million of unrestricted cash and zero debt.

Paysign reported its third quarter 2020 financial results, acknowledging the ongoing impact of the pandemic on its business, particularly affecting clients in the pharma and plasma industries. The company remains optimistic about recovery and targets a return to year-over-year growth, contingent on the pandemic's effects. Paysign is well-capitalized and anticipates an upturn in the fourth quarter from new client programs.

Paysign reported full year 2019 financial results, with revenues reaching $34.7 million, a 48% increase compared to 2018. Net income saw a significant increase of 188%, reaching $7.5 million. However, the company's fourth quarter performance contributed to missing the full year revenue guidance.